FDA and EMA Accept Fresenius Vedolizumab Biosimilar for Review

Regulatory authorities in both the United States and Europe have accepted the Vedolizumab biosimilar application for review, marking a significant step forward for a candidate biosimilar to intravenous use. This development strengthens Fresenius Kabi’s role in autoimmune therapies via an agreement granting global commercialization rights outside the Middle East and North Africa with Polpharma Biologics. The therapy targets adults with moderately to severely active ulcerative colitis or Crohn’s disease.

Regulatory Review of PB016 Biosimilar Application

Biosimilar applications demand rigorous demonstration of high similarity through analytical characterization, non-clinical studies, and clinical evaluations that meet agency standards. The PB016 biosimilar application incorporates a Phase 1 study in healthy volunteers and a Phase 3 trial in ulcerative colitis patients to compare efficacy, safety, and immunogenicity. These data underpin the Biologics License Application to the FDA and the Marketing Authorisation Application to the EMA.

Patient Impact and Vedolizumab Mechanism

Inflammatory bowel disease affects roughly 2.4 million people in the United States and 2.5 to 3 million across Europe, with rising incidence rates. Vedolizumab, a monoclonal antibody, selectively binds the α4β7 integrin to restrict lymphocyte migration into gastrointestinal tissue and ease inflammation. The PB016 biosimilar application positions this option within a vertically integrated biopharma model spanning research to commercialization, supporting Fresenius Kabi’s ability to supply complex biologics at scale.

Ad

Strategic Path to Broader Access

Acceptance of these filings advances the potential for expanded biologic availability within current healthcare budgets. The exclusive commercialization deal supports coordinated market entry that may shape pricing and reimbursement decisions post-approval. Continued progress on the PB016 biosimilar application aligns with Fresenius’ goal of increasing access to high-quality biologic medicines through established manufacturing and distribution networks. For full details on the regulatory acceptances, see the official announcement from Fresenius. This structured approach could ultimately ease treatment burdens for millions managing chronic inflammatory conditions.